{"id":"amil","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Fever"}]},"_chembl":null,"_dailymed":{"setId":"e0cc2d44-436a-47e8-a890-589882fff4c4","title":"AMILORIDE HYDROCHLORIDE TABLET [ENDO USA, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"aMIL (autologous Mutation-specific Immunotherapy for Lymphoma) is an individualized therapeutic cancer vaccine designed to stimulate T-cell responses against neoantigens derived from somatic mutations in a patient's own tumor. The vaccine is manufactured by sequencing the patient's tumor, identifying non-synonymous mutations, and creating a personalized immunogen that primes cytotoxic T lymphocytes to target cancer cells bearing these unique mutations.","oneSentence":"aMIL is a personalized neoantigen vaccine that trains the immune system to recognize and attack cancer cells expressing patient-specific tumor mutations.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T04:08:52.677Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Lymphoma (personalized neoantigen therapy)"}]},"trialDetails":[{"nctId":"NCT02342613","phase":"PHASE1","title":"Adoptive Immunotherapy With Activated Marrow Infiltrating Lymphocytes and Cyclophosphamide Graft-Versus-Host Disease Prophylaxis in Patients With Relapse of Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2015-05-28","conditions":"Hematologic Malignancies, Graft-Versus-Host Disease","enrollment":32},{"nctId":"NCT00566098","phase":"PHASE1, PHASE2","title":"Activated White Blood Cells With ASCT for Newly Diagnosed Multiple Myeloma","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2007-11","conditions":"Multiple Myeloma and Plasma Cell Neoplasm","enrollment":26},{"nctId":"NCT01045460","phase":"PHASE2","title":"Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2010-01-15","conditions":"Multiple Myeloma","enrollment":36},{"nctId":"NCT01858558","phase":"PHASE2","title":"Tadalafil and Lenalidomide Maintenance With or Without Activated Marrow Infiltrating Lymphocytes (MILs) in High Risk Myeloma","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2013-09","conditions":"Multiple Myeloma","enrollment":102}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"ALANINE AMINOTRANSFERASE INCREASED"},{"count":2,"reaction":"ALOPECIA"},{"count":2,"reaction":"ANAEMIA"},{"count":2,"reaction":"ANXIETY"},{"count":2,"reaction":"APPLICATION SITE EXFOLIATION"},{"count":2,"reaction":"ASPARTATE AMINOTRANSFERASE INCREASED"},{"count":2,"reaction":"ASTHENIA"},{"count":2,"reaction":"BACK PAIN"},{"count":2,"reaction":"BLOOD CREATININE INCREASED"},{"count":2,"reaction":"BLOOD DISORDER"}],"_approvalHistory":[],"publicationCount":64,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"aMIL","genericName":"aMIL","companyName":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","companyId":"sidney-kimmel-comprehensive-cancer-center-at-johns-hopkins","modality":"Biologic","firstApprovalDate":"","aiSummary":"aMIL is a personalized neoantigen vaccine that trains the immune system to recognize and attack cancer cells expressing patient-specific tumor mutations. Used for Lymphoma (personalized neoantigen therapy).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}